O
ARLZ

OrbiMed’s Aralez Pharmaceuticals Inc. ARLZ Stock Holding History

OrbiMed’s Portfolio ARLZ Stock Details ARLZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-68,143
Closed -$301K – 149
2016
Q4 		$301K Hold
68,143
– – ﹤0.01% 130
2016
Q3 		$330K Hold
68,143
– – ﹤0.01% 140
2016
Q2 		$225K Buy
+68,143
New +$257K ﹤0.01% 137

Other funds holding ARLZ

PCM
PAR Capital Management Boston, Massachusetts $3.45B AUM 28.5% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
ECP
Elk Creek Partners Denver, Colorado $582M AUM 10.23% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

OrbiMed's ARLZ Position: Q1 2017 in Review

OrbiMed sold out of Aralez Pharmaceuticals Inc. (ARLZ) in Q1 2017, closing a stake of 68,143 shares — an estimated $301K sold.

OrbiMed first reported a position in ARLZ in Q2 2016 and held it in 3 quarters. The position peaked at $330K in Q3 2016. 78 funds tracked by Wall St. Rank hold ARLZ as of Q1 2017.

  • OrbiMed reported no remaining Aralez Pharmaceuticals Inc. position as of Q1 2017 after selling out during the quarter.
  • OrbiMed sold 68,143 Aralez Pharmaceuticals Inc. shares in Q1 2017, an estimated $301K.
  • OrbiMed first reported a position in Aralez Pharmaceuticals Inc. in Q2 2016 and held it in 3 quarters.
  • OrbiMed's Aralez Pharmaceuticals Inc. position peaked at $330K in Q3 2016.
  • 78 funds tracked by Wall St. Rank held Aralez Pharmaceuticals Inc. as of Q1 2017.

Based on OrbiMed's 13F filing for Q1 2017, filed 15 May 2017.